Benzinga
Benzinga
Benzinga
jeudi, septembre 24

Definium Therapeutics Inc

DFTXNASDAQ
Trade with Public
Trade with Public
$37.48
-0.17-0.46%
Dern. MÀJ: Sep 24, 9:14 AM
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Definium Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Definium Therapeutics (DFTX).

Price Target Range — 3 Quarters

Analyst Consensus — 15 Analysts

15Buy
Consensus RatingBuy# Analysts15Avg. Consensus PT$64Upside to Avg. PT+69.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →
DateFirmAnalystActionRating ChangePrice Target
Sep 15, 2026Canaccord GenuitySumant KulkarniPT RaiseBuy$64→$78
Sep 15, 2026Baird Christopher ChenPT RaiseOutperform$75→$79
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $78

Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $64 to $78.
Benzinga Newsdesk

PRO
Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $79

Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $75 to $79.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Definium Therapeutics, Maintains $70 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $70 price target.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Definium Therapeutics, Maintains $66 Price Target

Needham analyst Ami Fadia reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $66 price target.
Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on Definium Therapeutics, Maintains $66 Price Target

RBC Capital analyst Brian Abrahams reiterates Definium Therapeutics (NASDAQ:DFTX) with a Outperform and maintains $66 price target.
Benzinga Newsdesk

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top analysts changed outlook on top names. See analyst ratings page for all changes.
Avi Kapoor

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved